A Look At Fresenius SE KGaA (XTRA:FRE) Valuation After The Latest Dividend Increase

Fresenius SE KGaA (XTRA:FRE) has announced an annual dividend of €1.05 per share, with the payout set for 27 May 2026, following an ex-dividend date of 25 May and a record date of 26 May. See our latest analysis for Fresenius SE KGaA. At a share price of €44.62, Fresenius SE KGaA has a 1 year total shareholder return of 17.09% and an 83.57% total shareholder return over three years, while the 90 day share price return of a 9.62% decline suggests some momentum has cooled despite gains over longer horizons. If this dividend move has you thinking about other healthcare names with potential growth drivers, it could be worth scanning 128 healthcare AI stocks With shares at €44.62, a value score of 6, an indicated intrinsic discount of 69% and a 24.96% gap to the average analyst price target, investors may ask whether Fresenius is underappreciated or whether the market is already pricing in future growth. Most Popular Narrative: 27% Undervalued Tokyo’s narrative points to a fair value of €61.46 per share, well above the recent €44.62 close, which sets up a very different story from the market price. What former CEO Mark Schneider blow up to an inefficient giant, will now be cut down by actual CEO Michael Sen and trimmed on efficiency from formally 4 segments FMC (dialyses), Helios (private hospitals), Kabi(Generic & Infusions), Vamed (Projects & Digitalization) only 2 remain, Helios, Kabi, the other will be sold, and the intakes will help to restructure the financial situation Read the complete narrative. This view leans heavily on Fresenius sharpening its focus, lifting margins and assigning a higher earnings multiple than the market currently applies. Curious which revenue and profit assumptions sit behind that gap to €61.46, and how they build a case for a higher long term valuation. Result: Fair Value of €61.46 (UNDERVALUED) Have a read of the narrative in full and understand what's behind the forecasts. However, this story can unwind if asset sales disappoint or if Helios and Kabi fail to translate portfolio focus into stronger profitability and cash generation. Find out about the key risks to this Fresenius SE KGaA narrative. Next Steps If this mix of optimism and concern feels familiar, act while the details are fresh. Carefully consider the trade off for yourself with 5 key rewards and 2 important warning signs Ready to hunt for more ideas? If you stop at a single company, you risk missing other opportunities with different risk and return profiles across sectors, sizes and balance sheet strengths. Target potentially mispriced names by scanning the market for companies that look cheap on quality and value metrics through the 233 high quality undervalued stocks Strengthen your income stream by focusing on resilient payers using the 480 dividend fortresses Prioritise stability and downside protection by filtering for companies with robust finances via the 300 resilient stocks with low risk scores This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.New: AI Stock Screener & AlertsOur new AI Stock Screener scans the market every day to uncover opportunities.• Dividend Powerhouses (3%+ Yield)• Undervalued Small Caps with Insider Buying• High growth Tech and AI CompaniesOr build your own from over 50 metrics.Explore Now for Free